Bremelanotide
- Generic Name
- Bremelanotide
- Brand Names
- Vyleesi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189691-06-3
- Unique Ingredient Identifier
- 6Y24O4F92S
- Background
Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women. Bremelanotide does not interact with alcohol. The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
...
- Indication
Bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug.
- Associated Conditions
- Hypoactive Sexual Desire Disorder (HSDD)
- Associated Therapies
- -
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06565611
- Locations
- 🇺🇸
University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand, Florida, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 16
- Registration Number
- NCT05709444
- Locations
- 🇺🇸
Northeast Research Center, LLC, Bethlehem, Pennsylvania, United States
🇺🇸Nephrotex Research Group, Dallas, Texas, United States
🇺🇸California Institute of Renal Research, Chula Vista, California, United States
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Kwang Dong Pharmaceutical co., ltd.
- Target Recruit Count
- 193
- Registration Number
- NCT04943068
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Imperial College Healthcare NHS Trust
- Target Recruit Count
- 40
- Registration Number
- NCT04179734
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03973047
- Locations
- 🇺🇸
ICON Early Phase Serrvices, LLC, San Antonio, Texas, United States
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 714
- Registration Number
- NCT02338960
- Locations
- 🇺🇸
Palatin Clinical Site 263, Atlanta, Georgia, United States
🇺🇸Palatin Clinical Site 204, Aventura, Florida, United States
🇺🇸Palatin Clinical Site 285, Charleston, West Virginia, United States
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 723
- Registration Number
- NCT02333071
- Locations
- 🇺🇸
Palatin Clinical Site 142, Savannah, Georgia, United States
🇺🇸Palatin Clinical Site 183, Bangor, Maine, United States
🇺🇸Palatin Clinical Site 108, Melbourne, Florida, United States
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 612
- Registration Number
- NCT01382719
- Locations
- 🇺🇸
Site 26, Huntsville, Alabama, United States
🇺🇸Site 64, Mobile, Alabama, United States
🇺🇸Site 52, National City, California, United States
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
- Conditions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Palatin Technologies, Inc
- Registration Number
- NCT00425256
- Locations
- 🇺🇸
Medford Women's Clinic, LLP, Medford, Oregon, United States
🇺🇸Advanced Biomedical Research, Inc, Hackensack, New Jersey, United States
🇺🇸Center for Sexual Medicine at Sheppard Pratt, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.